Holen Sie sich die Stockscreener-App
20.52
3.90%
0.665
Apellis Pharmaceuticals Inc Aktie (APLS) Neueste Nachrichten
APLS: Mizuho Maintains Rating, Raises Price Target | APLS Stock News - GuruFocus
Assessing Apellis Pharmaceuticals: Insights From 11 Financial Analysts - Benzinga
Update Recap: Will Apellis Pharmaceuticals Inc benefit from geopolitical trendsMarket Performance Summary & Daily Technical Forecast Reports - baoquankhu1.vn
Apellis Pharmaceuticals (APLS) director receives new stock options and RSUs - Stock Titan
Apellis (APLS) director Mikael Dolsten submits initial Form 3 insider filing - Stock Titan
Apellis Pharmaceuticals (APLS) Stock Analysis: Exploring a 62.73% Upside Potential in Biotech - DirectorsTalk Interviews
Apellis Pharmaceuticals Details SYFOVRE, EMPAVELI Growth Plans and FcRn Gene-Editing Push at TD Cowen Conf. - MarketBeat
Apellis adds former Pfizer research chief to board - Investing.com
Apellis Pharmaceuticals2026 Funding Rounds & List of Investors - Tracxn
Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Vanguard Group Inc. - MarketBeat
Apellis Pharmaceuticals Adds Mikael Dolsten to Board - TipRanks
Apellis Pharmaceuticals appoints Mikael Dolsten to board of directors - Investing.com
Apellis Announces Mikael Dolsten, M.D., Ph.D., to Join Board of Directors - Bitget
Mikael Dolsten joins Apellis Board as Class I director - TradingView
Mikael Dolsten joins Apellis (NASDAQ: APLS) board with equity grants - Stock Titan
Apellis Pharmaceuticals, Inc. Appoints Mikael Dolsten to Board of Directors, Effective March 1, 2026 - marketscreener.com
A Look At Apellis Pharmaceuticals (APLS) Valuation After 2025 Results And Softer Syfovre Growth Outlook - Sahm
Apellis Pharmaceuticals (NASDAQ:APLS) Lowered to Sell Rating by Wall Street Zen - MarketBeat
HC Wainwright Issues Optimistic Outlook for APLS Earnings - MarketBeat
Assessing Apellis Pharmaceuticals (APLS) Valuation After Prolonged Share Price Weakness - Yahoo Finance
Apellis (APLS) Q4 2025 Earnings Call Transcript - AOL.com
Analysts Issue Forecasts for APLS FY2030 Earnings - MarketBeat
Apellis price target lowered to $18 from $20 at Wedbush - Yahoo Finance
Apellis Pharmaceuticals Experiences Revision in Stock Evaluation Amidst Market Challenges - Markets Mojo
Apellis Profitability And Trial Progress Raise Questions On Valuation Gap - Sahm
Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million - AOL.com
S&E In Brief: Commercial Updates From The SMID Cap Universe - Citeline News & Insights
RBC Capital Adjusts Price Target for Apellis Pharmaceuticals (AP - GuruFocus
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Cut to $44.00 by Analysts at Citigroup - MarketBeat
APLS: Citigroup Maintains Rating, Lowers Price Target to $44.00 - GuruFocus
Mizuho Securities Adjusts Apellis Pharmaceuticals PT to $20 From $19, Maintains Neutral Rating - marketscreener.com
Royal Bank Of Canada Lowers Apellis Pharmaceuticals (NASDAQ:APLS) Price Target to $21.00 - MarketBeat
Apellis Q4 Loss Wider Than Expected, Revenues Decline Y/Y - Yahoo Finance
Why Apellis Pharmaceuticals Stock Is Under Pressure - TipRanks
RBC Capital Adjusts Apellis Pharmaceuticals PT to $21 From $22, Maintains Sector Perform Rating - marketscreener.com
Apellis Pharmaceuticals (NASDAQ:APLS) Price Target Lowered to $18.00 at Wedbush - MarketBeat
Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price Expected to Rise, HC Wainwright Analyst Says - MarketBeat
APLS: Analyst Wedbush Lowers Price Target to $18 While Maintaini - GuruFocus
Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) Q4 2025 Earnings Call Transcript - Insider Monkey
H.C. Wainwright raises Apellis stock price target on Syfovre outlook - Investing.com Australia
HC Wainwright & Co. Raises Price Target for APLS to $48.00 | APLS Stock News - GuruFocus
Apellis Pharmaceuticals Inc (APLS) Q4 2025 Earnings Call Highlig - GuruFocus
Decoding Apellis Pharmaceuticals Inc (APLS): A Strategic SWOT In - GuruFocus
Apellis Pharmaceuticals, Inc. (APLS) Stock Analysis: Exploring A 51% Upside Potential - DirectorsTalk Interviews
APLS Technical Analysis & ETF Price Forecast - Intellectia AI
Apellis Pharmaceuticals (APLS) Profitability Shift Tests Bullish Narratives After Q4 Loss - simplywall.st
Apellis Pharmaceuticals Q4 2025 Earnings Call Transcript - MarketBeat
Apellis Pharmaceuticals, Inc. Q4 2025 Earnings Call Summary - Yahoo Finance
Apellis Pharmaceuticals (NASDAQ:APLS) Shares Gap DownTime to Sell? - MarketBeat
Wedbush Adjusts Apellis Pharmaceuticals Price Target to $18 From $20, Maintains Neutral Rating - marketscreener.com
Apellis Pharmaceuticals, Inc. (APLS) Surpasses Q4 Earnings and Revenue Estimates - Bitget
Earnings call transcript: Apellis Pharmaceuticals Q4 2025 reveals strong product demand - Investing.com Nigeria
Apellis Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Apellis Pharmaceuticals, Inc. 2025 Q4ResultsEarnings Call Presentation (NASDAQ:APLS) 2026-02-24 - Seeking Alpha
Apellis Pharmaceuticals (NASDAQ:APLS) Announces Quarterly Earnings Results - MarketBeat
Apellis (APLS) Surpasses Revenue Expectations in Q4 - GuruFocus
APELLIS PHARMACEUTICALS ($APLS) Releases Q4 2025 Earnings - Quiver Quantitative
Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 Total Revenue $199.9M, vs. FactSet Est of $199.4M - marketscreener.com
Earnings Flash (APLS) Apellis Pharmaceuticals Posts Q4 EPS $0.47, vs. FactSet Est of $0.39 Loss - marketscreener.com
Apellis Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
Apellis Pharmaceuticals Earnings Report: Q4 Overview - Benzinga
Apellis Pharmaceuticals, Inc. SEC 10-K Report - TradingView
Eye and kidney drug maker Apellis hits $1B sales in 2025 - Stock Titan
APELLIS PHARMACEUTICALS INC (NASDAQ:APLS) Pairs Strong Growth with Bullish Chart Setup - ChartMill
0.50%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):